Cationic liposomes as vaccine adjuvants

References

• Christensen D, Korsholm KS, Rosenkrands I et al. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines6(5), 785–796 (2007).
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Christensen D, Bramwell VW et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J. Control. Release145(2), 102–108 (2010).
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Christensen D, Bramwell VW et al. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N’,N’-dimethylaminoethane)carbomyl] cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol. Pharm.8(1), 153–161 (2010).
   PubMedGoogle Scholar
• Joseph A, Itskovitz-Cooper N, Samira S et al. A new intranasal influenza vaccine based on a novel polycationic lipid–ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine24(18), 3990–4006 (2006).
   PubMed Web of Science ®Google Scholar
• Hilgers LA, Snippe H. DDA as an immunological adjuvant. Res. Immunol.143(5), 494–503; discussion 74–76 (1992).
   PubMedGoogle Scholar
• Brunel F, Darbouret A, Ronco J. Cationic lipid DC-Chol induces an improved and balanced immunity able to overcome the unresponsiveness to the hepatitis B vaccine. Vaccine17(17), 2192–2203 (1999).
   PubMed Web of Science ®Google Scholar
• Sanchez V, Gimenez S, Haensler J et al. Formulations of single or multiple H. pylori antigens with DC Chol adjuvant induce protection by the systemic route in mice. Optimal prophylactic combinations are different from therapeutic ones. FEMS Immunol. Med. Microbiol.30(2), 157–165 (2001).
   PubMedGoogle Scholar
• Vangasseri DP, Cui Z, Chen W et al. Immunostimulation of dendritic cells by cationic liposomes. Mol. Membr. Biol.23(5), 385–395 (2006).
   PubMed Web of Science ®Google Scholar
• Kuramoto T, Nishikawa M, Thanaketpaisarn O et al. Use of lipoplex-induced nuclear factor-κB activation to enhance transgene expression by lipoplex in mouse lung. J. Gene. Med.8(1), 53–62 (2006).
   PubMed Web of Science ®Google Scholar
• Zaks K, Jordan M, Guth A et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol.176(12), 7335–7345 (2006).
   PubMed Web of Science ®Google Scholar
• Mitchell LA, Joseph A, Kedar E, Barenholz Y, Galun E. Mucosal immunization against hepatitis A: antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid. Vaccine24(25), 5300–5310 (2006).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Legat A, Adam E et al. DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur. J. Immunol.38(5), 1351–1357 (2008).
   PubMed Web of Science ®Google Scholar
• Montier T, Benvegnu T, Jaffres PA, Yaouanc JJ, Lehn P. Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example. Curr. Gene Ther.8(5), 296–312 (2008).
   PubMed Web of Science ®Google Scholar
• Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit. Rev. Ther. Drug Carrier Syst.21(4), 257–317 (2004).
   PubMed Web of Science ®Google Scholar
• McLachlan G, Ho LP, Davidson-Smith H et al. Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP. Gene Ther.3(12), 1113–1123 (1996).
   PubMed Web of Science ®Google Scholar
• Porteous DJ, Dorin JR, McLachlan G et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther.4(3), 210–218 (1997).
   PubMed Web of Science ®Google Scholar
• McLachlan G, Stevenson BJ, Davidson DJ, Porteous DJ. Bacterial DNA is implicated in the inflammatory response to delivery of DNA/DOTAP to mouse lungs. Gene Ther.7(5), 384–392 (2000).
   PubMed Web of Science ®Google Scholar
• Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine19(23–24), 3301–3310 (2001).
   PubMed Web of Science ®Google Scholar
• Perrie Y, McNeil S, Vangala A. Liposome-mediated DNA immunisation via the subcutaneous route. J. Drug Target.11(8–10), 555–563 (2003).
   PubMed Web of Science ®Google Scholar
• Bei R, Guptill V, Masuelli L et al. The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice. J. Immunother.21(3), 159–169 (1998).
   PubMed Web of Science ®Google Scholar
• Shrivastava S, Lole KS, Tripathy AS, Shaligram US, Arankalle VA. Development of candidate combination vaccine for hepatitis E and hepatitis B: a liposome encapsulation approach. Vaccine27(47), 6582–6588 (2009).
   PubMed Web of Science ®Google Scholar
• Brgles M, Habjanec L, Halassy B, Tomasic J. Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response. Vaccine27(40), 5435–5442 (2009).
   PubMedGoogle Scholar
• Yan W, Huang L. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. Int. J. Pharm.368(1–2), 56–62 (2009).
   PubMed Web of Science ®Google Scholar
• Bal SM, Hortensius S, Ding Z, Jiskoot W, Bouwstra JA. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine29(5), 1045–1052 (2011).
   PubMed Web of Science ®Google Scholar
• Cui Z, Han SJ, Vangasseri DP, Huang L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol. Pharm.2(1), 22–28 (2005).
   PubMed Web of Science ®Google Scholar
• Yan W, Chen W, Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol.44(15), 3672–3681 (2007).
   PubMed Web of Science ®Google Scholar
• Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol. Immunother.57(4), 517–530 (2008).
   PubMed Web of Science ®Google Scholar
• Yan W, Chen W, Huang L. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J. Control. Release130(1), 22–28 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng JY, Huang HN, Tseng WC et al. Transcutaneous immunization by lipoplex-patch based DNA vaccines is effective vaccination against Japanese encephalitis virus infection. J. Control. Release135(3), 242–249 (2009).
   PubMed Web of Science ®Google Scholar
• Khazanov E, Simberg D, Barenholz Y. Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J. Gene Med.8(8), 998–1007 (2006).
   PubMed Web of Science ®Google Scholar
• Whitmore MM, Li S, Falo L Jr, Huang L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol. Immunother.50(10), 503–514 (2001).
   PubMed Web of Science ®Google Scholar
• Zhou S, Kawakami S, Yamashita F, Hashida M. Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Lett.287(1), 75–81 (2010).
   PubMed Web of Science ®Google Scholar
• Igarashi S, Hattori Y, Maitani Y. Biosurfactant MEL-A enhances cellular association and gene transfection by cationic liposome. J. Control. Release112(3), 362–368 (2006).
   PubMed Web of Science ®Google Scholar
• Maitani Y, Igarashi S, Sato M, Hattori Y. Cationic liposome (DC-Chol/DOPE = 1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression. Int. J. Pharm.342(1–2), 33–39 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li H, Sun J et al. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int. J. Pharm.390(2), 198–207 (2010).
   PubMed Web of Science ®Google Scholar
• Guy B, Pascal N, Francon A et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine19(13–14), 1794–1805 (2001).
   PubMed Web of Science ®Google Scholar
• Vangala A, Bramwell VW, McNeil S et al. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. J. Control. Release119(1), 102–110 (2007).
   PubMed Web of Science ®Google Scholar
• Pialoux G, Hocini H, Pérusat S et al. Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study. Vaccine26(21), 2657–2666 (2008).
   PubMed Web of Science ®Google Scholar
• Cremel M, Hamzeh-Cognasse H, Genin C, Delezay O. Female genital tract immunization: evaluation of candidate immunoadjuvants on epithelial cell secretion of CCL20 and dendritic/Langerhans cell maturation. Vaccine24(29–30), 5744–5754 (2006).
   PubMed Web of Science ®Google Scholar
• Dalsgaard K. Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch. Gesamte Virusforsch.44(3), 243–254 (1974).
   PubMedGoogle Scholar
• Myschik J, Eberhardt F, Rades T, Hook S. Immunostimulatory biodegradable implants containing the adjuvant Quil-A – part I: physicochemical characterisation. J. Drug Target.16(3), 213–223 (2008).
   PubMed Web of Science ®Google Scholar
• Myschik J, McBurney WT, Rades T, Hook S. Immunostimulatory lipid implants containing Quil-A and DC-cholesterol. Int. J. Pharm.363(1–2), 91–98 (2008).
   PubMedGoogle Scholar
• McBurney WT, Lendemans DG, Myschik J et al.In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine26(35), 4549–4556 (2008).
   PubMed Web of Science ®Google Scholar
• Solodin I, Brown CS, Bruno MS et al. A novel series of amphiphilic imidazolinium compounds for in vitro and in vivo gene delivery. Biochemistry34(41), 13537–13544 (1995).
   PubMed Web of Science ®Google Scholar
• McLean JW, Fox EA, Baluk P et al. Organ-specific endothelial cell uptake of cationic liposome–DNA complexes in mice. Am. J. Physiol.273(1 Pt 2), H387–H404 (1997).
   PubMed Web of Science ®Google Scholar
• Dow SW, Fradkin LG, Liggitt DH et al. Lipid–DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol.163(3), 1552–1561 (1999).
   PubMed Web of Science ®Google Scholar
• Freimark BD, Blezinger HP, Florack VJ et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J. Immunol.160(9), 4580–4586 (1998).
   PubMed Web of Science ®Google Scholar
• Hofland H, Huang L. Inhibition of human ovarian carcinoma cell proliferation by liposome–plasmid DNA complex. Biochem. Biophys. Res. Commun.207(2), 492–496 (1995).
   PubMed Web of Science ®Google Scholar
• Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther.6(11), 1867–1875 (1999).
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature408(6813), 740–745 (2000).
   PubMed Web of Science ®Google Scholar
• Gowen BB, Fairman J, Dow S et al. Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res.81(1), 37–46 (2009).
   PubMedGoogle Scholar
• Gowen BB, Fairman J, Smee DF et al. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome–DNA complexes. Antiviral Res.69(3), 165–172 (2006).
   PubMed Web of Science ®Google Scholar
• Ireland R, Olivares-Zavaleta N, Warawa JM et al. Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Path.6(5), e1000921 (2010).
   PubMedGoogle Scholar
• Morrey JD, Motter NE, Taro B, Lay M, Fairman J. Efficacy of cationic lipid–DNA complexes (CLDC) on hepatitis B virus in transgenic mice. Antiviral Res.79(1), 71–79 (2008).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Cardin RD, Bravo FJ et al. Potent adjuvant activity of cationic liposome–DNA complexes for genital herpes vaccines. Clin. Vac. Immunol.16(5), 699–705 (2009).
   PubMedGoogle Scholar
• Chang S, Warner J, Liang L, Fairman J. A novel vaccine adjuvant for recombinant flu antigens. Biologicals37(3), 141–147 (2009).
   PubMed Web of Science ®Google Scholar
• Cote PJ, Butler SD, George AL et al. Rapid immunity to vaccination with woodchuck hepatitis virus surface antigen using cationic liposome–DNA complexes as adjuvant. J. Med. Virol.81(10), 1760–1772 (2009).
   PubMed Web of Science ®Google Scholar
• Lay M, Callejo B, Chang S et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine27(29), 3811–3820 (2009).
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev.8(4), 247–258 (2008).
   Google Scholar
• Fairman J, Moore J, Lemieux M et al. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome–DNA complexes in a rhesus macaque pilot study. Hum. Vaccin.5(3), 141–150 (2009).
   PubMed Web of Science ®Google Scholar
• Jones A, Bosio C, Duffy A et al. Protection against pneumonic plague following oral immunization with a non-replicating vaccine. Vaccine28(36), 5924–5929 (2010).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Farley N, Bravo FJ et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine28(21), 3748–3753 (2010).
   PubMed Web of Science ®Google Scholar
• Troyer RM, Propst KL, Fairman J, Bosio CM, Dow SW. Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis. Vaccine27(33), 4424–4433 (2009).
   PubMed Web of Science ®Google Scholar
• Goodyear A, Kellihan L, Bielefeldt-Ohmann H et al. Protection from pneumonic infection with Burkholderia species by inhalational immunotherapy. Infect. Immun.77(4), 1579–1588 (2009).
   PubMed Web of Science ®Google Scholar
• Benatti CR, Ruysschaert JM, Lamy MT. Structural characterization of DiC14-amidine, a pH-sensitive cationic lipid used for transfection. Chem. Phys. Lipids.131(2), 197–204 (2004).
   PubMedGoogle Scholar
• Ruysschaert JM, el Ouahabi A, Willeaume V et al. A novel cationic amphiphile for transfection of mammalian cells. Biochem. Biophys. Res. Commun.203(3), 1622–1628 (1994).
   PubMed Web of Science ®Google Scholar
• Jacquet A, Vanderschrick JF, Vandenbranden M et al. Vaccination with the recombinant allergen ProDer p 1 complexed with the cationic lipid DiC14-amidine prevents allergic responses to house dust mite. Mol. Ther.11(6), 960–968 (2005).
   PubMed Web of Science ®Google Scholar
• Lonez C, Legat A, Vandenbranden M, Ruysschaert JM. DiC14-amidine confers new anti-inflammatory properties to phospholipids. Cell. Mol. Life Sci.65(4), 620–630 (2008).
   PubMedGoogle Scholar
• Lonez C, Vandenbranden M, Ouali M et al. Free diC14-amidine liposomes inhibit the TNF-α secretion induced by CpG sequences and lipopolysaccharides: role of lipoproteins. Mol. Membr. Biol.23(3), 227–234 (2006).
   PubMed Web of Science ®Google Scholar
• Gall D. The adjuvant activity of aliphatic nitrogenous bases. Immunology11(4), 369–386 (1966).
   PubMed Web of Science ®Google Scholar
• Stanfield JP, Gall D, Bracken PM. Single-dose antenatal tetanus immunisation. Lancet301(7797), 215–219 (1973).
   Google Scholar
• Veronesi R, Correa A, Alterio D. Single dose immunization against tetanus. Promising results in human trials. Rev. Inst. Med. Trop.12(1), 46–54 (1970).
   PubMedGoogle Scholar
• Hilgers LA, Snippe H, Jansze M, Willers JM. Combinations of two synthetic adjuvants: synergistic effects of a surfactant and a polyanion on the humoral immune response. Cell. Immunol.92(2), 203–209 (1985).
   PubMedGoogle Scholar
• Henriksen-Lacey M, Bramwell VW, Christensen D et al. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J. Control. Release142(2), 180–186 (2010).
   PubMed Web of Science ®Google Scholar
• Korsholm KS, Agger EM, Foged C et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology121(2), 216–226 (2007).
   PubMed Web of Science ®Google Scholar
• Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun.68(2), 791–795 (2000).
   PubMed Web of Science ®Google Scholar
• Casella C, Mitchell T. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci.65(20), 3231–3240 (2008).
   PubMed Web of Science ®Google Scholar
• Sable SB, Verma I, Khuller GK. Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis. Vaccine23(32), 4175–4184 (2005).
   PubMed Web of Science ®Google Scholar
• Agger EM, Cassidy JP, Brady J et al. Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection. Immunology124(2), 175–185 (2008).
   PubMed Web of Science ®Google Scholar
• Langermans JA, Doherty TM, Vervenne RA et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine23(21), 2740–2750 (2005).
   PubMed Web of Science ®Google Scholar
• Korsholm KS, Petersen RV, Agger EM, Andersen P. T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology129(1), 75–86 (2010).
   PubMed Web of Science ®Google Scholar
• Bekierkunst A, Yarkoni E, Flechner I et al. Immune response to sheep red blood cells in mice pretreated with mycobacterial fractions. Infect. Immun.4(3), 256–263 (1971).
   PubMed Web of Science ®Google Scholar
• Lima VM, Bonato VL, Lima KM et al. Role of trehalose dimycolate in recruitment of cells and modulation of production of cytokines and NO in tuberculosis. Infect. Immun.69(9), 5305–5312 (2001).
   PubMed Web of Science ®Google Scholar
• Ryll R, Kumazawa Y, Yano I. Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids – a review. Microbiol. Immunol.45(12), 801–811 (2001).
   PubMed Web of Science ®Google Scholar
• Silva CL, Ekizlerian SM, Fazioli RA. Role of cord factor in the modulation of infection caused by mycobacteria. Am. J. Pathol.118(2), 238–247 (1985).
   PubMed Web of Science ®Google Scholar
• Hunter RL, Olsen M, Jagannath C, Actor JK. Trehalose 6,6’-dimycolate and lipid in the pathogenesis of caseating granulomas of tuberculosis in mice. Am. J. Pathol.168(4), 1249–1261 (2006).
   PubMed Web of Science ®Google Scholar
• Hunter RL, Olsen MR, Jagannath C, Actor JK. Multiple roles of cord factor in the pathogenesis of primary, secondary, and cavitary tuberculosis, including a revised description of the pathology of secondary disease. Ann. Clin. Lab. Sci.36(4), 371–386 (2006).
   PubMedGoogle Scholar
• Hunter RL, Venkataprasad N, Olsen MR. The role of trehalose dimycolate (cord factor) on morphology of virulent M. tuberculosis in vitro. Tuberculosis86(5), 349–356 (2006).
   PubMedGoogle Scholar
• Werninghaus K, Babiak A, Gross O et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRγ-Syk-Card9-dependent innate immune activation. J. Exp. Med.206(1), 89–97 (2009).
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Ishikawa T, Morita YS et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med.206(13), 2879–2888 (2009).
   PubMed Web of Science ®Google Scholar
• Matsunaga I, Moody DB. Mincle is a long sought receptor for mycobacterial cord factor. J. Exp. Med.206(13), 2865–2868 (2009).
   PubMed Web of Science ®Google Scholar
• Schoenen H, Bodendorfer B, Hitchens K et al. Cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol.184(6), 2756–2760 (2010).
   PubMed Web of Science ®Google Scholar
• Davidsen J, Rosenkrands I, Christensen D et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6’-dibehenate) – a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta1718(1–2), 22–31 (2005).
   PubMed Web of Science ®Google Scholar
• Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect. Immun.72(3), 1608–1617 (2004).
   PubMed Web of Science ®Google Scholar
• Christensen D, Kirby D, Foged C et al.α,α’-trehalose 6,6’-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. Biochim. Biophys. Acta1778(5), 1365–1373 (2008).
   PubMed Web of Science ®Google Scholar
• Agger EM, Rosenkrands I, Hansen J et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE3(9), e3116 (2008).
   PubMed Web of Science ®Google Scholar
• Christensen D, Lindenstrom T, van de Wijdeven G, Andersen P, Agger EM. Syringe free vaccination with CAF01 adjuvated Ag85B-ESAT-6 in Bioneedles™ provides strong and prolonged protection against tuberculosis. PLoS ONEe15043 (2010).
   PubMedGoogle Scholar
• Lindenstrom T, Agger EM, Korsholm KS et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol.182(12), 8047–8055 (2009).
   PubMed Web of Science ®Google Scholar
• Hansen J, Jensen KT, Follmann F et al. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J. Infect. Dis.198(5), 758–767 (2008).
   PubMed Web of Science ®Google Scholar
• Olsen AW, Theisen M, Christensen D, Follmann F, Andersen P. Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model. PLoS ONE5(5), e10768 (2010).
   PubMedGoogle Scholar
• Yu H, Jiang X, Shen C et al.Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of γ interferon (IFN-γ)/tumor necrosis factor α and IFN-γ/interleukin-17 double-positive CD4+ T cells. Infect. Immun.78(5), 2272–2282 (2010).
   PubMed Web of Science ®Google Scholar
• Kamath AT, Rochat AF, Christensen D et al. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells. PLoS ONE4(6), e5771 (2009).
   PubMed Web of Science ®Google Scholar
• Kamath AT, Henri S, Battye F, Tough DF, Shortman K. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood100(5), 1734–1741 (2002).
   PubMed Web of Science ®Google Scholar
• Nordly P, Agger EM, Andersen P, Nielsen HM, Foged C. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo. Pharm. Res.28(3), 553–562 (2011).
   PubMed Web of Science ®Google Scholar
• Andersen CS, Agger EM, Rosenkrands I et al. A simple mycobacterial monomycolated glycerol lipid has potent immunostimulatory activity. J. Immunol.182(1), 424–432 (2009).
   PubMed Web of Science ®Google Scholar
• Andersen CA, Rosenkrands I, Olsen AW et al. Novel generation mycobacterial adjuvant based on liposome-encapsulated monomycoloyl glycerol from Mycobacterium bovis bacillus Calmette–Guerin. J. Immunol.183(4), 2294–2302 (2009).
   PubMed Web of Science ®Google Scholar
• Bhowruth V, Minnikin DE, Agger EM et al. Adjuvant properties of a simplified C32 monomycolyl glycerol analogue. Bioorg. Med. Chem. Lett.19(7), 2029–2032 (2009).
   PubMed Web of Science ®Google Scholar
• Nordly P, Korsholm KS, Pedersen EA et al. Incorporation of a synthetic mycobacterial monomycoloyl glycerol analogue stabilizes dimethyldioctadecylammonium liposomes and potentiates their adjuvant effect in vivo. Eur. J. Pharm. Biopharm.77(1), 89–98 (2011).
   PubMed Web of Science ®Google Scholar
• Bhowmick S, Ravindran R, Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect. Immun.76(3), 1003–1015 (2008).
   PubMed Web of Science ®Google Scholar